Close Menu

NEW YORK ─ Vela Diagnostics said on Wednesday that it has received Emergency Use Authorization from the US Food and Drug Administration for its ViroKey SARS-CoV-2 RT-PCR Test v2.0.

The automated probe-based RT-PCR test detects SARS-CoV-2 in nasopharyngeal and oropharyngeal swabs and is optimized for a workflow consisting of Vela Diagnostics' Sentosa SX101 and Sentosa SA201 instruments. The test enables high-throughput testing of up to 46 samples in a single run with reduced hands-on time, Vela said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.